Page 1

May 12 , 2021 KIORA PHARMACEUTICALS EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update -PP - 001 : proof - of - concept study in Austria for dry eye patients expected to initiate in Q3 : 21 ; U.S. IND submission planned in Q4 : 21- -OBG : U.S. IND submission and initiation of Phase 2 dry eye study is planned in Q4 : 21 ; proof - of - concept study for persistent epithelial defects expected to initiate in Q4 : 21- -PP - 001 for systemic indications : Phase 1 healthy volunteer study in Austria planned to initiate in Q4 : 21- WALTHAM , Mass . , May 12 , 2021 ( GLOBE NEWSWIRE ) -- EyeGate Pharmaceuticals , Inc. ( NASDAQ : EYEG ) , ( " EyeGate " or the " Company " ) , a clinical - stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases , today reported its financial results for the quarter ended March 31 , 2021 and provided an update on recent corporate and operational activities . " We have entered a new phase of strategic growth and are steadily executing across our clinical development program for PP - 001 and OBG , two unique platforms with broad therapeutic potential among a diverse range of ocular surface and systemic diseases , " said Franz Obermayr , Ph.D. , Acting Chief Executive Officer of EyeGate . " We look forward to providing updates on our progress as we plan to kick - off several new clinical initiatives this year . " Recent Business Highlights : Pipeline updates Ocular Surface Franchise • PP - 001 is an inhibitor of dihydroorotate dehydrogenase ( " DHODH ” ) and first - in - class for ophthalmology indications . PP - 001 has been successfully formulated as an ophthalmic eye drop for conjunctivitis and dry eye disease ( “ DED ” ) . We have completed a Phase 1 safety study in healthy volunteers and expect to move forward with the following : 。 Initiate a proof - of - concept study in dry eye patients in Austria inQ3 2021 . 。 File an IND in the U.S. in Q4 2021 . • Ocular Bandage Gel ( " OBG ” ) eye drop is based on a modified form of the natural polymer hyaluronic acid ( " HA ” ) designed to protect the ocular surface , permit re- epithelialization of the cornea , and improve ocular surface integrity . OBG has been developed to address ophthalmic conditions where epithelial cells are either missing ( wounds ) or compromised ( epitheliopathies ) .